

Special Issue

Epidemiology and Prevention of Avian Immunosuppressive Diseases

Message from the Guest Editors

Avian immunosuppressive diseases could damage the immune organs of poultry to a certain extent and significantly reduce their multiple immune functions, leading to vaccination failure, mixed infection, secondary infection, etc., which would bring direct and indirect economic losses to the poultry industry worldwide. At present, an increasing number of poultry diseases have been proved to have immunosuppressive effects; however, the prevention and control methods of avian immunosuppressive diseases still need to be further studied. This Special Issue aims to focus on the epidemiology and prevention of avian immunosuppressive diseases, including research on epidemiology, virus isolation and identification, vaccine development, and testing methods. Furthermore, our topic will cover various immunosuppressive diseases, including, but not limited to, infectious bursal disease virus (IBDV), avian leukosis virus (ALV), Marek's disease virus (MDV), avian reovirus (ARV), avian influenza virus (AIV), and Newcastle disease virus (NDV). Both original research and review articles are welcome.

Guest Editors

Dr. Aijing Liu

Dr. Yang Li

Dr. Tuanjie Wang

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/155447

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).